{"id":"insulin-analog-mid-mixture","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin analog mid-mixture products combine rapid-acting and intermediate-acting insulin analogs in a fixed ratio to provide both immediate and sustained glucose control. The rapid-acting component begins working within minutes to address postprandial (after-meal) glucose spikes, while the intermediate-acting component provides basal insulin coverage over several hours. Together, they approximate the physiologic insulin secretion pattern in non-diabetic individuals.","oneSentence":"This insulin analog mixture mimics natural insulin by binding to insulin receptors to promote glucose uptake and utilization in cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:07.741Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03018938","phase":"PHASE4","title":"A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-02-06","conditions":"Type 2 Diabetes Mellitus","enrollment":814},{"nctId":"NCT00393705","phase":"PHASE4","title":"Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 2","enrollment":302}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Insulin Analog Mid Mixture","genericName":"Insulin Analog Mid Mixture","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This insulin analog mixture mimics natural insulin by binding to insulin receptors to promote glucose uptake and utilization in cells. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}